<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924079</url>
  </required_header>
  <id_info>
    <org_study_id>NAL001</org_study_id>
    <secondary_id>TSGHIRB096-02-010-I</secondary_id>
    <nct_id>NCT00924079</nct_id>
  </id_info>
  <brief_title>The Development of Oral Nalbuphine Dosage Form</brief_title>
  <acronym>NAL</acronym>
  <official_title>Pharmacokinetic Study of Oral Nalbuphine in Normal Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tri-Service General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate possible responses to pharmacokinetic properties&#xD;
      for nalbuphine oral formulations in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter eq Cmax, AUC, Cl, T1/2</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>nalbuphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine</intervention_name>
    <description>oral dosage form, 66 mg, single dose</description>
    <arm_group_label>nalbuphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal healthy adult subjects between 20-40 years of age.&#xD;
&#xD;
          -  Body weight within 80-120% of ideal body weight. Ideal body weight = (height-80)0.7&#xD;
&#xD;
          -  Acceptable medical history and physical examination including:&#xD;
&#xD;
               -  Normal chest X-ray and ECG results within six months prior to Period I dosing.&#xD;
&#xD;
               -  No particular clinical significance in general disease history within two months&#xD;
                  prior to Period I dosing.&#xD;
&#xD;
          -  Acceptable clinical laboratory determinations without significant deviation from&#xD;
             normal values within two months prior to Period I dosing, which includes:&#xD;
&#xD;
               -  AST (SGOT)&#xD;
&#xD;
               -  ALT (SGPT)&#xD;
&#xD;
               -  Gama-GT&#xD;
&#xD;
               -  alkaline phosphatase&#xD;
&#xD;
               -  total bilirubin&#xD;
&#xD;
               -  albumin&#xD;
&#xD;
               -  glucose&#xD;
&#xD;
               -  BUN&#xD;
&#xD;
               -  uric acid&#xD;
&#xD;
               -  creatinine&#xD;
&#xD;
               -  total cholesterol&#xD;
&#xD;
               -  triglyceride(TG)&#xD;
&#xD;
          -  Acceptable hematology within two months prior to the study, which includes hemoglobin,&#xD;
             hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white&#xD;
             blood cells and platelets.&#xD;
&#xD;
          -  Acceptable urinalysis within two months prior to the study, which includes pH, blood,&#xD;
             glucose and protein.&#xD;
&#xD;
          -  Signed the written informed consent to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent history of drug or alcohol addiction or abuse.&#xD;
&#xD;
          -  A clinically significant disorder involving the cardiovascular, respiratory, renal,&#xD;
             gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or&#xD;
             psychiatric disease (as determined by the clinical investigator).&#xD;
&#xD;
          -  History of allergic response(s) to nalbuphine or related drugs.&#xD;
&#xD;
          -  History of clinically significant allergies including drug allergies or allergic&#xD;
             bronchial asthma.&#xD;
&#xD;
          -  Evidence of chronic or acute infectious diseases.&#xD;
&#xD;
          -  Any clinically significant illness or surgery during the four weeks prior to Period I&#xD;
             dosing (as determined by the clinical investigator).&#xD;
&#xD;
          -  Taking any drug known to induce or inhibit hepatic drug metabolism within one month&#xD;
             prior to the beginning of the study.&#xD;
&#xD;
          -  Receiving any investigational drug within one month prior to Period I dosing.&#xD;
&#xD;
          -  Taking any prescription medication or any nonprescription medication within two weeks&#xD;
             prior to Period I doing.&#xD;
&#xD;
          -  Donating greater than 150 ml of blood within two months prior to Period I dosing or&#xD;
             donating plasma (e.g., plasmapheresis) within 14 days prior to Period I dosing. All&#xD;
             subjects will be advised not to donate blood for four weeks after completing the&#xD;
             study.&#xD;
&#xD;
          -  Consumption of caffeine, xanthine-containing products (i.e., coffee, tea,&#xD;
             caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol at least 48 hours&#xD;
             prior to days on which dosing is scheduled and during the periods when blood samples&#xD;
             are being collected.&#xD;
&#xD;
          -  Any other medical reason as determined by the clinical investigator.&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding. Women of childbearing potential must have a&#xD;
             negative urine pregnancy test at Baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tri-Service General Hospitial</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Shung-Tai, MD</last_name>
      <phone>886-2-87927125</phone>
      <email>painlab@ndmctsgh.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Ho Shung-Tai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>June 18, 2009</last_update_submitted>
  <last_update_submitted_qc>June 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ho Shung-Tai/Professor of the department of anesthsiology</name_title>
    <organization>Department of anesthsiology of Tri-service General Hospitial</organization>
  </responsible_party>
  <keyword>Analysis of plasma concentration of nalbuphine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

